At close: December 13 at 4:00:00 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 2 |
| Avg. Estimate | -0.09 | -0.09 | -0.5 | -8.23 |
| Low Estimate | -0.09 | -0.09 | -0.5 | -16.08 |
| High Estimate | -0.09 | -0.09 | -0.5 | -0.38 |
| Year Ago EPS | -4.45 | -4.12 | -16.85 | -0.5 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 1 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -3.12 | -4.1 | -3.98 | -3.95 |
| EPS Actual | -4.45 | -4.12 | -3.86 | -2.2 |
| Difference | -1.33 | -0.02 | 0.12 | 1.75 |
| Surprise % | -42.42% | -0.44% | 3.02% | 44.35% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.09 | -0.09 | -0.5 | -8.23 |
| 7 Days Ago | -3.95 | -3.95 | -16.12 | -15.94 |
| 30 Days Ago | -3.95 | -3.95 | -16.12 | -15.94 |
| 60 Days Ago | -3.95 | -3.95 | -16.12 | -15.94 |
| 90 Days Ago | -0.15 | 0 | -0.63 | -8.35 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NCNA | 98.02% | 97.86% | 97.02% | -1,538.65% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | Oppenheimer: Outperform to Outperform | 8/19/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 7/23/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 7/22/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 4/1/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 11/21/2023 |
| Reiterates | Truist Securities: Buy to Buy | 9/6/2023 |
Related Tickers
ALLR Allarity Therapeutics, Inc.
1.0200
-0.97%
HOTH Hoth Therapeutics, Inc.
0.8100
-2.80%
GLMD Galmed Pharmaceuticals Ltd.
2.9700
+6.45%
NBY NovaBay Pharmaceuticals, Inc.
0.5749
+3.10%
XRTX XORTX Therapeutics Inc.
1.1900
+1.71%
TOVX Theriva Biologics, Inc.
1.1800
-0.84%
HCWB HCW Biologics Inc.
0.3570
-7.75%
PRTG Portage Biotech Inc.
3.0000
-22.28%
ALZN Alzamend Neuro, Inc.
1.1900
0.00%
LPTX Leap Therapeutics, Inc.
2.9500
-5.75%